Loading...
BVMF
BIOM3
Market cap166mUSD
Jul 09, Last price  
6.09BRL
1D
-2.40%
1Q
-17.14%
Jan 2017
-1.46%
IPO
425.43%
Name

Biomm SA

Chart & Performance

D1W1MN
BVMF:BIOM3 chart
P/E
—
P/S
3.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.42%
Rev. gr., 5y
35.63%
Revenues
269m
+88.45%
6,645,0001,995,0003,017,000608,000877,000231,00000000103,0001,566,0008,944,00058,668,000107,090,000104,954,000118,194,000142,905,000269,299,000
Net income
-7m
L-91.34%
6,000-5,318,000-7,414,000-5,727,000-4,273,000-4,675,000-14,140,000-10,059,000-12,713,0008,282,000-45,608,000-38,128,000-42,562,000-55,812,000-70,767,000-80,261,000-92,559,000-81,141,000-77,238,000-6,687,000
CFO
-112m
L+21.85%
-5,715,000-7,496,000-4,640,000-1,782,000-7,227,000-10,508,000-19,784,000-13,899,000-38,281,000-54,405,000-44,115,000-77,606,000-96,874,000-93,784,000-62,999,000-74,785,000-91,845,000-111,915,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biomm S.A. is a biotechnology enterprise based in Brazil. Its diverse product portfolio features pharmaceutical and healthcare solutions, including AFREZZA, a human insulin administered as an inhalation powder, and GLARGILIN, a type of glargine insulin. The company also supplies HERZUMA, a trastuzumab, and CONFORT CARE, a moisturizing foot cream. Biomm S.A. was established in 2001 and maintains its headquarters in São Paulo, Brazil.
URL
https://biomm.com/
IPO date
Sep 05, 2002
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT